1
|
Latifi M, Sani M, Salmannejad M, Kabir-Salmani M, Babakhanzadeh Bavanati H, Talaei-Khozani T. Synergistic impact of platelet rich plasma-heparin sulfate with hydroxyapatite/zirconia on the osteoblast differentiation potential of adipose-derived mesenchymal stem cells. Cell Tissue Bank 2021; 23:669-683. [PMID: 34665403 DOI: 10.1007/s10561-021-09966-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 09/13/2021] [Indexed: 11/24/2022]
Abstract
3D porous hydroxyapatite (HA) has been reinforced by zirconia (ZrO2) coating and impregnation with a combination of platelet rich plasma (PRP) as a source of growth factors (GFs) and Heparin sulfate (HS) to sustain the release of GFs. Adipose mesenchymal stem cells (ADMSCs) were characterized by flow cytometry for CD (cluster of differentiation) 44, CD105, CD106, CD34 and CD144, along with checking the multipotency by differentiation into the adipocytes and osteoblasts. Then, they were cultured on the scaffold treated with and without osteogenic media on days 7, 14 and 21. Electron micrograph and PKH staining show that the ADMSCs have a fusiform phenotype in the absence of osteogenic induction. Cell viability assay shows a higher number of the viable cells on the PRP-containing scaffolds than PRP-free scaffolds on day 7. Colorimetric evaluation, quantitative RT-PCR and immunocytochemistry demonstrate that PRP and HS significantly elevate the alkaline phosphatase enzyme activity and also accelerate the production of both early and mid-osteogenic markers, including collagen I and osteopontin expression with and without osteogenic conditions. The PRP-HS also accelerates the expression of the late osteogenic marker, osteocalcin, in both mRNA and protein level expression with a peak on day 21. In conclusion, supplementation of HA/ZrO2 with PRP/HS has a synergistic impact on the ADMSCs, even in the absence of chemical induction. It seems that HA/ZrO2/PRP/HS scaffold provides a higher osteoconductive microenvironment for stem cell differentiation to osteoblasts.
Collapse
Affiliation(s)
- Mona Latifi
- Tissue Engineering Lab, Anatomy Department, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mahsa Sani
- Department of Tissue Engineering, School of Advanced Medical Science and Technologies, Shiraz University of Medical Science, Shiraz, Iran
| | - Mahin Salmannejad
- Tissue Engineering Lab, Anatomy Department, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Maryam Kabir-Salmani
- Department of Stem Cell and Regenerative Medicine, Medical Biotechnology Faculty, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
| | | | - Tahereh Talaei-Khozani
- Tissue Engineering Lab, Anatomy Department, Shiraz University of Medical Sciences, Shiraz, Iran.
| |
Collapse
|
2
|
Quang Le B, Chun Tan T, Lee SB, Woong Jang J, Sik Kim Y, Soo Lee J, Won Choi J, Sathiyanathan P, Nurcombe V, Cool SM. A biomimetic collagen-bone granule-heparan sulfate combination scaffold for BMP2 delivery. Gene 2020; 769:145217. [PMID: 33039540 DOI: 10.1016/j.gene.2020.145217] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Accepted: 10/05/2020] [Indexed: 01/17/2023]
Abstract
Bone morphogenetic protein 2 (BMP2)-induced bone regeneration is most efficacious when a carrier can deliver the growth factor into the defect site while minimizing off-target effects. The control of BMP2 release by such carriers is proving one of the most critical aspects of BMP2 therapy. Thus, increasing numbers of biomaterials are being developed to satisfy the simultaneous need for sustained release, reduced rates of degradation and enhanced activity of the growth factor. Here we report on a biomimetic scaffold consisting of bovine collagen type I, bone granules (Intergraft™), and heparan sulfate with increased affinity for BMP2 (HS3). The HS3 and collagen were complexed and then crosslinked via a simple dehydrothermal method. When loaded with a clinically relevant amount of BMP2 (1.25 mg/cc), the HS3-functionalised scaffolds were able to retain up to 58% of the initial amount of BMP2 over 27 days, approximately 3-fold higher than scaffolds without HS3. The bioactivity of the retained BMP2 was confirmed by gene expression in myoblast cells (C2C12) cultured on the scaffolds under osteogenic stimulation. Together these data demonstrate the efficacy of HS3 as a material to improve the performance collagen/bone granule-based scaffolds.
Collapse
Affiliation(s)
- Bach Quang Le
- Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648, Singapore
| | - Tuan Chun Tan
- Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648, Singapore
| | - Seong-Baek Lee
- Cellumed CO LTD, 130. Digital-ro, Geumcheon-gu (Gasan-dong, Acetechno tower-9th), Seoul, Republic of Korea
| | - Ju Woong Jang
- Cellumed CO LTD, 130. Digital-ro, Geumcheon-gu (Gasan-dong, Acetechno tower-9th), Seoul, Republic of Korea
| | - Young Sik Kim
- Cellumed CO LTD, 130. Digital-ro, Geumcheon-gu (Gasan-dong, Acetechno tower-9th), Seoul, Republic of Korea
| | - Jung Soo Lee
- Cellumed CO LTD, 130. Digital-ro, Geumcheon-gu (Gasan-dong, Acetechno tower-9th), Seoul, Republic of Korea
| | - Jae Won Choi
- Cellumed CO LTD, 130. Digital-ro, Geumcheon-gu (Gasan-dong, Acetechno tower-9th), Seoul, Republic of Korea
| | - Padmapriya Sathiyanathan
- Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648, Singapore
| | - Victor Nurcombe
- Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648, Singapore
| | - Simon M Cool
- Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648, Singapore; Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119288, Singapore.
| |
Collapse
|
3
|
Abstract
Heparin and heparan sulfate (HS) are polydisperse mixtures of polysaccharide chains between 5 and 50 kDa. Sulfate modifications to discreet regions along the chains form protein binding sites involved in cell signaling cascades and other important cellular physiological and pathophysiological functions. Specific protein affinities of the chains vary among different tissues and are determined by the arrangements of sulfated residues in discreet regions along the chains which in turn appear to be determined by the expression levels of particular enzymes in the biosynthetic pathway. Although not all the rules governing synthesis and modification are known, analytical procedures have been developed to determine composition, and all of the biosynthetic enzymes have been identified and cloned. Thus, through cell engineering, it is now possible to direct cellular synthesis of heparin and HS to particular compositions and therefore particular functional characteristics. For example, directing heparin producing cells to reduce the level of a particular type of polysaccharide modification may reduce the risk of heparin induced thrombocytopenia (HIT) without reducing the potency of anticoagulation. Similarly, HS has been linked to several biological areas including wound healing, cancer and lipid metabolism among others. Presumably, these roles involve specific HS compositions that could be produced by engineering cells. Providing HS reagents with a range of identified compositions should help accelerate this research and lead to new clinical applications for specific HS compositions. Here I review progress in engineering CHO cells to produce heparin and HS with compositions directed to improved properties and advancing medical research.
Collapse
|
4
|
Le BQ, Rai B, Hui Lim ZX, Tan TC, Lin T, Lin Lee JJ, Murali S, Teoh SH, Nurcombe V, Cool SM. A polycaprolactone-β-tricalcium phosphate-heparan sulphate device for cranioplasty. J Craniomaxillofac Surg 2018; 47:341-348. [PMID: 30579746 DOI: 10.1016/j.jcms.2018.11.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 10/09/2018] [Accepted: 11/12/2018] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Cranioplasty is a surgical procedure used to treat a bone defect or deformity in the skull. To date, there is little consensus on the standard-of-care for graft materials used in such a procedure. Graft materials must have sufficient mechanical strength to protect the underlying brain as well as the ability to integrate and support new bone growth. Also, the ideal graft material should be individually customized to the contours of the defect to ensure a suitable aesthetic outcome for the patient. PURPOSE Customized 3D-printed scaffolds comprising of polycaprolactone-β-tricalcium phosphate (PCL-TCP) have been developed with mechanical properties suitable for cranioplasty. Osteostimulation of PCL-TCP was enhanced through the addition of a bone matrix-mimicking heparan sulphate glycosaminoglycan (HS3) with increased affinity for bone morphogenetic protein-2 (BMP-2). Efficacy of this PCL-TCP/HS3 combination device was assessed in a rat critical-sized calvarial defect model. METHOD Critical-sized defects (5 mm) were created in both parietal bones of 19 Sprague Dawley rats (Male, 450-550 g). Each cranial defect was randomly assigned to 1 of 4 treatment groups: (1) A control group consisting of PCL-TCP/Fibrin alone (n = 5); (2) PCL-TCP/Fibrin-HSft (30 μg) (n = 6) (HSft is the flow-through during HS3 isolation that has reduced affinity for BMP-2); (3) PCL-TCP/Fibrin-HS3 (5 μg) (n = 6); (4) PCL-TCP/Fibrin-HS3 (30 μg) (n = 6). Scaffold integration and bone formation was evaluated 12-weeks post implantation by μCT and histology. RESULTS Treatment with PCL-TCP/Fibrin alone (control) resulted in 23.7% ± 1.55% (BV/TV) of the calvarial defect being filled with new bone, a result similar to treatment with PCL-TCP/Fibrin scaffolds containing either HSft or HS3 (5 μg). At increased amounts of HS3 (30 μg), enhanced bone formation was evident (BV/TV = 38.6% ± 9.38%), a result 1.6-fold higher than control. Further assessment by 2D μCT and histology confirmed the presence of enhanced bone formation and scaffold integration with surrounding host bone only when scaffolds contained sufficient bone matrix-mimicking HS3. CONCLUSION Enhancing the biomimicry of devices using a heparan sulphate with increased affinity to BMP-2 can serve to improve the performance of PCL-TCP scaffolds and provides a suitable treatment for cranioplasty.
Collapse
Affiliation(s)
- Bach Quang Le
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648
| | - Bina Rai
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648
| | - Zophia Xue Hui Lim
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648
| | - Tuan Chun Tan
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648
| | - Tingxuan Lin
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648
| | - Jaslyn Jie Lin Lee
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648
| | - Sadasivam Murali
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648
| | - Swee Hin Teoh
- Centre for Bone Tissue Engineering, School of Chemical and Biomedical Engineering, Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 62 Nanyang Drive, 637459, Singapore
| | - Victor Nurcombe
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648
| | - Simon McKenzie Cool
- Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648; Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119288.
| |
Collapse
|
5
|
Faivre L, Parietti V, Siñeriz F, Chantepie S, Gilbert-Sirieix M, Albanese P, Larghero J, Vanneaux V. In vitro and in vivo evaluation of cord blood hematopoietic stem and progenitor cells amplified with glycosaminoglycan mimetic. Stem Cell Res Ther 2016; 7:3. [PMID: 26742480 PMCID: PMC4705640 DOI: 10.1186/s13287-015-0267-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Revised: 12/08/2015] [Accepted: 12/18/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Expansion protocols aim at both increasing the number of umbilical cord blood (UCB) hematopoietic stem cells and progenitor cells (HSPCs) and reducing the period of neutropenia in UCB HSPC graft. Because glycosaminoglycans (GAGs) are known to be important components of the hematopoietic niche and to modulate growth factor effects, we explored the use of GAG mimetic OTR4131 to potentiate HSPC's in vitro expansion and in vivo engraftment. METHODS UCB CD34+ cells were expanded with serum-free medium, SCF, TPO, FLT3-lig and G-CSF during 12 days in the absence or the presence of increasing OTR4131 concentrations (0-100 μg/mL). Proliferation ratio, cell viability and phenotype, functional assays, migration capacity and NOD-scid/γc(-/-) mice engraftment were assessed after expansion. RESULTS At Day 12, ratios of cell expansion were not significantly increased by OTR4131 treatment. Better total nucleated cell viability was observed with the use of 1 μg/mL GAG mimetic compared to control (89.6 % ± 3.7 % and 79.9 % ± 3.3 %, respectively). Phenotype analysis showed a decrease of monocyte lineage in the presence of OTR4131 and HSPC migration capacity was diminished when GAG mimetic was used at 10 μg/mL (10.9 % ± 4.1 % vs. 52.9 % ± 17.9 % for control). HSPC clonogenic capacities were similar whatever the culture conditions. Finally, in vivo experiments revealed that mice successfully engrafted in all conditions, even if some differences were observed during the first month. Three months after graft, bone marrow chimerism and blood subpopulations were similar in both groups. CONCLUSIONS UCB HSPCs ex-vivo expansion in the presence of OTR4131 is a safe approach that did not modify cell function and engraftment capacities. In our experimental conditions, the use of a GAG mimetic did not, however, allow increasing cell expansion or optimizing their in vivo engraftment.
Collapse
Affiliation(s)
- Lionel Faivre
- Inserm, U 1160, Centre d'Investigation Clinique en Biothérapies, 75010, Paris, France. .,AP-HP, Hôpital Saint-Louis, Unité de Thérapie Cellulaire, Paris, F-75010, France.
| | - Véronique Parietti
- Département d'Expérimentation d'Animale, Université́ Paris Diderot, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, F-75010, France.
| | | | - Sandrine Chantepie
- Université Paris Est Créteil, Université Paris Est, EA 4397 ERL CNRS 9215, Laboratoire CRRET, 61 Avenue du Général de Gaulle, 94010, Créteil, France.
| | | | - Patricia Albanese
- Université Paris Est Créteil, Université Paris Est, EA 4397 ERL CNRS 9215, Laboratoire CRRET, 61 Avenue du Général de Gaulle, 94010, Créteil, France.
| | - Jérôme Larghero
- Inserm, U 1160, Centre d'Investigation Clinique en Biothérapies, 75010, Paris, France. .,AP-HP, Hôpital Saint-Louis, Unité de Thérapie Cellulaire, Paris, F-75010, France. .,Université Paris Diderot, Sorbonne Paris Cité, U 1160, Paris, F-75010, France.
| | - Valérie Vanneaux
- Inserm, U 1160, Centre d'Investigation Clinique en Biothérapies, 75010, Paris, France. .,AP-HP, Hôpital Saint-Louis, Unité de Thérapie Cellulaire, Paris, F-75010, France.
| |
Collapse
|
6
|
Lee J, Wee S, Gunaratne J, Chua RJE, Smith RAA, Ling L, Fernig DG, Swaminathan K, Nurcombe V, Cool SM. Structural determinants of heparin-transforming growth factor-β1 interactions and their effects on signaling. Glycobiology 2015; 25:1491-504. [PMID: 26306634 DOI: 10.1093/glycob/cwv064] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Accepted: 08/08/2015] [Indexed: 12/28/2022] Open
Abstract
Transforming growth factor-β1 (TGF-β1, Uniprot: P01137) is a heparin-binding protein that has been implicated in a number of physiological processes, including the initiation of chondrogenesis by human mesenchymal stem cells (hMSCs). Here, we identify the molecular features in the protein and in heparin required for binding and their effects on the potentiation of TGF-β1's activity on hMSCs. Using a proteomics "Protect and Label" approach, lysines K291, K304, K309, K315, K338, K373, K375 and K388 were identified as being directly involved in binding heparin (Data are available via ProteomeXchange with identifier PXD002772). Competition assays in an optical biosensor demonstrated that TGF-β1 does require N- and 6-O-sulfate groups for binding but that 2-O-sulfate groups are unlikely to underpin the interaction. Heparin-derived oligosaccharides as short as degree of polymerization (dp) 4 have a weak ability to compete for TGF-β1 binding to heparin, which increases with the length of the oligosaccharide to reach a maximum between dp18 and dp24. In cell-based assays, heparin, 2-O-, 6-O- and N-desulfated re-N-acetylated heparin and oligosaccharides 14-24 saccharides (dp14-24) in length all increased the phosphorylation of mothers against decapentaplegic homolog 2 (SMAD2) after 6 h of stimulation with TGF-β1. The results provide the structural basis for a model of heparin/heparan sulfate binding to TGF-β1 and demonstrate that the features in the polysaccharide required for binding are not identical to those required for sustaining the signaling by TGF-β1 in hMSCs.
Collapse
Affiliation(s)
- Jonathan Lee
- NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore, Singapore 117456 Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore, Singapore 138648
| | - Sheena Wee
- Quantitative Proteomics Group, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore 138673
| | - Jayantha Gunaratne
- Quantitative Proteomics Group, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore 138673
| | - R J E Chua
- Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore, Singapore 138648
| | - Raymond A A Smith
- Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore, Singapore 138648
| | - Ling Ling
- Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore, Singapore 138648
| | - David G Fernig
- Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
| | | | - Victor Nurcombe
- Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore, Singapore 138648 Lee Kong Chian School of Medicine, Nanyang Technological University-Imperial College, Singapore, Singapore 639798
| | - Simon M Cool
- Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore, Singapore 138648 Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| |
Collapse
|
7
|
Gesslbauer B, Theuer M, Schweiger D, Adage T, Kungl AJ. New targets for glycosaminoglycans and glycosaminoglycans as novel targets. Expert Rev Proteomics 2013; 10:77-95. [PMID: 23414361 DOI: 10.1586/epr.12.75] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Biological functions of a variety of proteins are mediated via their interaction with glycosaminoglycans (GAGs). The structural diversity within the wide GAG landscape provides individual interaction sites for a multitude of proteins involved in several pathophysiological processes. This 'GAG angle' of such proteins as well as their specific GAG ligands give rise to novel therapeutic concepts for drug development. Current glycomic technologies to elucidate the glycan structure-function relationships, methods to investigate the selectivity and specificity of glycan-protein interactions and existing therapeutic approaches to interfere with GAG-protein interactions are discussed.
Collapse
Affiliation(s)
- Bernd Gesslbauer
- ProtAffin Biotechnologie AG, Reininghausstrasse 13a, 8020 Graz, Austria
| | | | | | | | | |
Collapse
|
8
|
Murali S, Rai B, Dombrowski C, Lee JLJ, Lim ZXH, Bramono DS, Ling L, Bell T, Hinkley S, Nathan SS, Hui JH, Wong HK, Nurcombe V, Cool SM. Affinity-selected heparan sulfate for bone repair. Biomaterials 2013; 34:5594-605. [PMID: 23632323 DOI: 10.1016/j.biomaterials.2013.04.017] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Accepted: 04/07/2013] [Indexed: 12/01/2022]
Abstract
Bone morphogenetic protein (BMP)-2 is a potent bone healing compound produced at sites of bone trauma. Here we present a therapeutic strategy to harness the activity of endogenously produced BMP-2 by delivery of an affinity-matched heparan sulfate (HS) glycos aminoglycan biomaterial that increases the bioavailability, bioactivity and half-life of this growth factor. We have developed a robust, cost effective, peptide-based affinity platform to isolate a unique BMP-2 binding HS variant from commercially available preparations of HS, so removing the manufacturing bottleneck for their translation into the clinic. This affinity-matched HS enhanced BMP-2-induced osteogenesis through improved BMP-2 kinetics and receptor modulation, prolonged pSMAD signaling and reduced interactions with its antagonist noggin. When co-delivered with a collagen implant, the HS was as potent as exogenous BMP-2 for the healing of critical-sized bone defects in rabbits. This affinity platform can be readily tuned to isolate HS variants targeted ata range of clinically-relevant growth and adhesive factors.
Collapse
Affiliation(s)
- S Murali
- Glycotherapeutics Group, Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648, Singapore
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Bramono DS, Murali S, Rai B, Ling L, Poh WT, Lim ZX, Stein GS, Nurcombe V, van Wijnen AJ, Cool SM. Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2). Bone 2012; 50:954-64. [PMID: 22227436 PMCID: PMC3589980 DOI: 10.1016/j.bone.2011.12.013] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2011] [Revised: 12/16/2011] [Accepted: 12/17/2011] [Indexed: 11/29/2022]
Abstract
Lowering the efficacious dose of bone morphogenetic protein-2 (BMP-2) for the repair of critical-sized bone defects is highly desirable, as supra-physiological amounts of BMP-2 have an increased risk of side effects and a greater economic burden for the healthcare system. To address this need, we explored the use of heparan sulfate (HS), a structural analog of heparin, to enhance BMP-2 activity. We demonstrate that HS isolated from a bone marrow stromal cell line (HS-5) and heparin each enhances BMP-2-induced osteogenesis in C2C12 myoblasts through increased ALP activity and osteocalcin mRNA expression. Commercially available HS variants from porcine kidney and bovine lung do not generate effects as great as HS5. Heparin and HS5 influence BMP-2 activity by (i) prolonging BMP-2 half-life, (ii) reducing interactions between BMP-2 with its antagonist noggin, and (iii) modulating BMP2 distribution on the cell surface. Importantly, long-term supplementation of HS5 but not heparin greatly enhances BMP-2-induced bone formation in vitro and in vivo. These results show that bone marrow-derived HS effectively supports bone formation, and suggest its applicability in bone repair by selectively facilitating the delivery and bioavailability of BMP-2.
Collapse
Affiliation(s)
- Diah S. Bramono
- Stem Cells and Tissue Repair Group, Institute of Medical Biology, A*STAR (Agency for Science Technology and Research), Biopolis, Singapore 138648
| | - Sadasivam Murali
- Stem Cells and Tissue Repair Group, Institute of Medical Biology, A*STAR (Agency for Science Technology and Research), Biopolis, Singapore 138648
| | - Bina Rai
- Stem Cells and Tissue Repair Group, Institute of Medical Biology, A*STAR (Agency for Science Technology and Research), Biopolis, Singapore 138648
| | - Ling Ling
- Stem Cells and Tissue Repair Group, Institute of Medical Biology, A*STAR (Agency for Science Technology and Research), Biopolis, Singapore 138648
| | - Wei Theng Poh
- Stem Cells and Tissue Repair Group, Institute of Medical Biology, A*STAR (Agency for Science Technology and Research), Biopolis, Singapore 138648
| | - Zophia Xuehui Lim
- Stem Cells and Tissue Repair Group, Institute of Medical Biology, A*STAR (Agency for Science Technology and Research), Biopolis, Singapore 138648
| | - Gary S. Stein
- Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts 01655
| | - Victor Nurcombe
- Stem Cells and Tissue Repair Group, Institute of Medical Biology, A*STAR (Agency for Science Technology and Research), Biopolis, Singapore 138648
- Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074
| | - Andre J. van Wijnen
- Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts 01655
| | - Simon M. Cool
- Stem Cells and Tissue Repair Group, Institute of Medical Biology, A*STAR (Agency for Science Technology and Research), Biopolis, Singapore 138648
- Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074
| |
Collapse
|
10
|
Bramono DS, Rider DA, Murali S, Nurcombe V, Cool SM. The Effect of Human Bone Marrow Stroma-Derived Heparan Sulfate on the Ex Vivo Expansion of Human Cord Blood Hematopoietic Stem Cells. Pharm Res 2010; 28:1385-94. [DOI: 10.1007/s11095-010-0352-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Accepted: 12/10/2010] [Indexed: 11/28/2022]
|